Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

NCT06712472 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

554

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer
p53abn

Interventions

DRUG: Olaparib (300 mg BID)

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]